Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

Blood (2023) 142 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2023-178778

Published: 2023

Journal Articles

Factors Influencing Lymphocyte Collection Efficiency for the Manufacture of CAR-T Cells in Adults with B Cell Malignancies , a Single Center Experience

Safia Belbachir, Duncan Purtill, Paolo Chiappini, Scott Clair, Allison A Barraclough

Blood (2023) 142 (Supplement 1): 2148.

https://doi.org/10.1182/blood-2023-185009

Published: 2023

Journal Articles

Predictive Value of Pre-Infusion FDG‐PET/CT Parameters for Clinical Outcomes and Toxicities in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following CAR-T Cell Therapy

Safia Belbachir, Sweeka Alexander, Mayank Dhamija, Zeyad Al-Ogaili, Duncan Purtill, Allison A Barraclough

Blood (2023) 142 (Supplement 1): 6319.

https://doi.org/10.1182/blood-2023-185051

Published: 2023

Journal Articles

Ibrutinib for Steroid Refractory Chronic Graft Vs Host Disease - Real World Experience

Gaurav Sutrave, Tishya Indran, Yatika Jivan, Andrew Hutchison, Nada Hamad, Sui Tan, Duncan Purtill, Andrew Grigg, Siok-Keen Tey, David J. Curtis, David J Gottlieb, Abir Bhattacharyya

Blood (2022) 140 (Supplement 1): 10537–10539.

https://doi.org/10.1182/blood-2022-168683

Published: 2022

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Emma Verner, Amanda Johnston, Nalini Pati, Eliza Hawkes, Hui-Peng Lee, Tara Cochrane, Chan-Yoon Cheah, Robin J Filshie, Duncan Purtill, Hanlon Sia, Anoop Kumar Enjeti, Christina Brown, Nicholas E. Murphy, Jennifer Curnow, Kenneth Lee, Mannu Walia, Belinda Butcher, Judith Trotman

Blood (2021) 138 (Supplement 1): 304.

https://doi.org/10.1182/blood-2021-149019

Published: 2021

Journal Articles

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Kirsty M Sharplin, MBBS, David Ritchie, MB ChB, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Shyam Panicker, MBBS,MDMRCP,FRACP,FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Julian Cooney, FRACP,FRCPA,MBBS,, Richard Doocey, MB ChB, FRACP, FRCPA, Leanne Berkahn, MD, Sam Milliken, MBBS, FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Andrew Spencer, David J. Curtis, MBBS,PhD, Sushrut S. Patil, Stephen R Larsen, MBBS PhDFRACP FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Matthew Greenwood, MBBS, FRACP, FRCPA, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Eric Wong, MDPhD FRACP, FRCPA, Steven Tran, BEng MBiomedE, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-138684

Published: 2020

Journal Articles

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

John Moore, MB.BS, MD FRACP, FRCPA, John Kwan, MBBS,FRACP,FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ashish Bajel, FRACP, David Ritchie, MB ChB, PhD FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Steven Tran, BEng MBiomedE, Donna Aarons, B.Pharm, Nada Hamad, MB.BS, FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-142131

Published: 2020

Journal Articles

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Portia Smallbone, MBBS, Stephanie Clugston, MBBS (Hons), Rebecca De Kraa, BSc, Duncan Purtill, MBBS,FRCPA,FRACP, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-141783

Published: 2020

Journal Articles

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Stephanie Clugston, MBBS (Hons), Portia Smallbone, MBBS, Duncan Purtill, MBBS,FRCPA,FRACP, Dustin Hall, MBBS,FRCPA,FRACP, Rebecca De Kraa, BSc, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141784

Published: 2020

Journal Articles

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136574

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, David Gottlieb, MBBS, MD FRACP, FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Stephen R Larsen, MBBS PhDFRACP FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Simon Durrant, MBBS FRCP FRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Cameron Curley, MBBS, FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-139057

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Stephen R Larsen, MBBS PhDFRACP FRCPA, Andrew Spencer, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Simon Durrant, MBBS FRCP FRCPath, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Hugh J. Goodman, FRACP, Ian H. Kerridge, FRACP FRCPA MPhil BA, Christopher Arthur, Cameron Curley, MBBS, FRACP, FRCPA, Caroline Stewart, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Jennifer Collins, Julian Cooney, FRACP,FRCPA,MBBS,, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139076

Published: 2020

Journal Articles

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Eliza A Hawkes, Hui-Peng Lee, MBChB, FRACP, FRCPA, BHB, Tara Cochrane, MBBS,FRCPA,FRACP, Chan Y. Cheah, Duncan Purtill, MBBS,FRCPA,FRACP, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, Christina Brown, PhDFRACP,FRCPA,MBBS, Nicholas E. Murphy, FRCPA,MBBS,FRACP, Jennifer Curnow, MBBS, FRACP, FRCPA, PhD, Julia Carlson, Belinda Butcher, BSci, MBiostat, PhD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4094.

https://doi.org/10.1182/blood-2019-124621

Published: 2019

Journal Articles

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Blood (2019) 134 (Supplement_1): 5719.

https://doi.org/10.1182/blood-2019-126547

Published: 2019

Journal Articles

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

James Anton Kuzich, MBBS, Andrew Peter Hutchison, MBBS, Kenneth Lim, MBBS, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Gavin Cull, MB, BS, FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, David John Longstaff Joske, Dejan Radeski, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP

Blood (2017) 130 (Supplement 1): 1524.

https://doi.org/10.1182/blood.V130.Suppl_1.1524.1524

Published: 2017

Journal Articles

An International Multicenter Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Patients with Transplant-Eligible Mantle Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4052.

https://doi.org/10.1182/blood.V130.Suppl_1.4052.4052

Published: 2017

Journal Articles

Day 45 Lymphocyte Recovery Is Independently Associated with Transplant-Related Mortality after Adult Myeloablative Double-Unit Cord Blood Transplantation (dCBT)

Duncan Purtill, FRACP,FRCPA,MBBS, Doris M. Ponce, MD, Sean M. Devlin, PhD, Marissa N Lubin, BA, Parastoo B Dahi, MD, Sergio A Giralt, MD, Miguel-Angel Perales, MD, Richard J. O'Reilly, MD, Marcel R.M. van den Brink, MD PhD, James W. Young, MD, Andromachi Scaradavou, MD, Cladd Stevens, MD, Juliet N. Barker, MBBS(Hons), FRACP

Blood (2014) 124 (21): 1156.

https://doi.org/10.1182/blood.V124.21.1156.1156

Published: 2014

Journal Articles

Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect

Duncan Purtill, FRACP,FRCPA,MBBS, Marissa N Lubin, BA, Doris M. Ponce, MD, Sergio Giralt, MD, Miguel-Angel Perales, MD, Richard J O'Reilly, MD, Marcel Van Den Brink, MD PhD, James W. Young, MD, Andromachi Scaradavou, MD, Cladd Stevens, MD, Juliet N. Barker, MBBS(Hons), FRACP

Blood (2014) 124 (21): 2459.

https://doi.org/10.1182/blood.V124.21.2459.2459

Published: 2014

Journal Articles

Dominant unit CD34 + cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice

Duncan Purtill, Katherine Smith, Sean Devlin, Richard Meagher, Joann Tonon, Marissa Lubin, Doris M. Ponce, Sergio Giralt, Nancy A. Kernan, Andromachi Scaradavou, Cladd E. Stevens, Juliet N. Barker

Blood (2014) 124 (19): 2905–2912.

https://doi.org/10.1182/blood-2014-03-566216

Published: 2014

Includes: Supplemental data

NARROW

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

Factors Influencing Lymphocyte Collection Efficiency for the Manufacture of CAR-T Cells in Adults with B Cell Malignancies , a Single Center Experience

Predictive Value of Pre-Infusion FDG‐PET/CT Parameters for Clinical Outcomes and Toxicities in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following CAR-T Cell Therapy

Ibrutinib for Steroid Refractory Chronic Graft Vs Host Disease - Real World Experience

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

An International Multicenter Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Patients with Transplant-Eligible Mantle Cell Lymphoma

Day 45 Lymphocyte Recovery Is Independently Associated with Transplant-Related Mortality after Adult Myeloablative Double-Unit Cord Blood Transplantation (dCBT)

Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect

Dominant unit CD34 + cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only